RNA interference targeting Fas protects mice from fulminant hepatitis

By Erwei Song, Sang-Kyung Lee, Jie Wang, N. Ince, N. Ouyang, J. Min, Ji-sheng Chen, P. Shankar, J. Lieberman. Nature Medicine, 2003

1,135 citations recorded by the source corpus.

Subfields: Animal Science and Zoology, Epidemiology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/660aa19408514f2f4e34792dcffedc351cf66a28

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Animal Science and Zoology

1. John J. Rossi
2. M. Kay
3. J. Kurreck

In Epidemiology

1. John J. Rossi

In Molecular Biology

1. Carlo Maria Croce
2. George A. Calin
3. John J. Rossi
4. M. Ferracin
5. Robert Langer
6. Chang-Gong Liu
7. Daniel G. Anderson
8. L. Aagaard

Citations in the corpus

• Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. (2004, background): “However, this promise is tempered by their double-stranded RNA (dsRNA) oligonucleotide nature, resembling antisense, ribozymes and gene therapy (6,7).”
• RNA therapeutics: Beyond RNA interference and antisense oligonucleotides (2012, background): “Notably, a first successful in vivo study was carried out as early as 2003, using naked siRNA to knockdown FAS mRNA in a mouse model of fulminant hepatiti”
• In vivo imaging of siRNA delivery and silencing in tumors (2007, background): “There have been numerous reports of in vivo gene silencing with siRNAs, including hydrodynamic injection of synthetic siRNA (refs”
• Inhibition of respiratory viruses by nasally administered siRNA (2005, background): “In pioneering recent work, siRNA offered protection from hepatitis virus, and siRNA against the Fas antigen prevented liver damage resulting from fulminant hepatiti”
• Resolution of liver cirrhosis using vitamin A–coupled liposomes to deliver siRNA against a collagen-specific chaperone (2008, background): “75 mg/kg per single injection) was less than doses previously shown to have in vivo therapeutic effect”
• Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors (2005, background): “Early studies validating the therapeutic potential of siRNAs in mice used high-pressure (so-called hydrodynamic) intravenous injection to force siRNAs into cell”
• Interfering with disease: a progress report on siRNA-based therapeutics (2007, background): “From the first in vivo evidence of RNAi-based therapeutic efficacy in an animal disease model in 2003 (REF. 3 ), the pace of drug development has been rapid.”
• siRNA delivery systems for cancer treatment. (2009, background): “The hydrodynamic injection of Fas-specific siRNA prevented liver failure in mice with chronic and severe autoimmune hepatitis [12].”
• RNAi therapeutics: principles, prospects and challenges. (2007, methodology): “Anti-Fas siRNAs were hydrodynamically injected into the antibody treated mice resulting in 82% of the treated mice surviving for 10 days of observation, whereas all control mice died within 3 days [79].”
• The promises and pitfalls of RNA-interference-based therapeutics (2009, neutral): “This was followed by the first therapeutic application of siRNAs: siRNAs were targeted to Fas mRNA in a mouse model of autoimmune hepatitis, resulting in protection of the treated animals against liver fibrosi”
• Inhibition of hepatitis B virus in mice by RNA interference (2003, background): “Fas siRNA treatment protected mice from fulminant hepatitis induced by injecting agonistic Fas-specific antibod”